Oxurion Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Pascal Ghoson

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	no data
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Pascal Ghoson

less than a year

Tenure

Mr. Pascal Ghoson is Administrative & Financial Director of SA Energisme from May 2023. He serves as a Director of Hopium SA since September 05, 2023. He serves as an Chief Financial Officer and Executive...

Board Members

Name	Position	Tenure	Compensation	Ownership
Pascal Ghoson	CEO, CFO & Executive Director	less than a year	no data	no data
James Hartmann	Independent Non-Executive Director	less than a year	no data	no data
Charles de Bollardiere	Independent Chairman of the Board	less than a year	no data	no data
Nathalie Laarakker	Non-Executive	1.6yrs	€34.92k	no data
Anat Loewenstein	Non-Executive	1.6yrs	€26.92k	no data

0.8yrs

Average Tenure

Experienced Board: 0G99's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Oxurion Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Oxurion NV, Annual General Meeting, May 07, 2024

High number of new and inexperienced directors

Oxurion Announces CEO Changes

Recent updates

Oxurion NV (ENXTBR:OXUR) signed a letter of intent to acquire 80% stake in Contract Research Organisation for €9.8 million.

High number of new and inexperienced directors

High number of new and inexperienced directors

Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)

New minor risk - Financial data availability

Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024

High number of new and inexperienced directors

Oxurion NV, Annual General Meeting, May 07, 2024

High number of new and inexperienced directors

Oxurion Announces CEO Changes

Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)

Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023

Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema

High number of new and inexperienced directors

Less than half of directors are independent

Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis

Oxurion NV Announces Interim Analysis for KALAHARI Trial

Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

Oxurion NV, Annual General Meeting, May 02, 2023

Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Full year 2021 earnings released: €0.76 loss per share (vs €0.73 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Oxurion NV Announces New Data on THR-149 Phase 2 Clinical Trial in DME At the Angiogenesis, Exudation, and Degeneration 2022 Conference

Oxurion Provides Update on Clinical Pipeline Progress

Oxurion NV announced that it has received €10 million in funding from Pontifax Ltd., Kreos Capital Management (UK) Limited

OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Full year 2020 earnings released: €0.73 loss per share (vs €1.35 loss in FY 2019)

Oxurion NV announced that it expects to receive €30 million in funding from Negma Group Ltd.

Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)

Oxurion NV to Report Fiscal Year 2020 Final Results on Apr 05, 2021

Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer

Oxurion NV to Report Fiscal Year 2021 Results on Mar 17, 2022

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Oxurion NV Announces Executive Changes

Baron Philippe Vlerick, Non-Executive member of the Board of ThromboGenics NV acquired 3.6% stake in ThromboGenics NV (ENXTBR:THR).

Oxurion NV(ENXTBR:OXUR) dropped from S&P Global BMI Index

CEO

Tenure

Board Members

Average Tenure